The Global Epstein-Barr Virus (EBV) Market is driven by rising prevalence of associated diseases
The Epstein-Barr virus (EBV) market comprises diagnostics, therapeutics and preventive vaccines for EBV. Diagnostic products detect if a person has been infected with EBV through blood tests that detect EBV antibodies. Therapeutics include antiviral drugs that fight EBV or controls its symptoms. Preventive vaccines protect people from getting infected with EBV. EBV is a herpes virus that infects over 90% of adults worldwide and is the cause of infectious mononucleosis and linked to several cancers and autoimmune diseases. As EBV has no symptoms in most people, diagnosis is required for certain at-risk groups.
The Epstein-Barr Virus (EBV) market is estimated to be valued at USD 1.4 Billion in 2024 and is expected to reach USD 2.1 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.53% from 2024 to 2031.
The growing prevalence of infectious mononucleosis, cancers and autoimmune diseases associated with Epstein-Barr Virus (EBV) Market has been driving the demand for EBV diagnostics, therapeutics and vaccines. As per WHO, over 95% of adults globally have been infected by EBV by the age of 40. Timely diagnosis of EBV is crucial for managing associated diseases.
Get more insights on: Epstein-Barr Virus (EBV) Market
Get this Report in Japanese Language: エプスタイン・バーウイルス（EBV）市場
Get this Report in Korean Language: 엡스타인-바 바이러스(EBV) 시장
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian